Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.
J Clin Immunol
; 42(6): 1130-1136, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35538387
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Limits:
Humans
Language:
En
Journal:
J Clin Immunol
Year:
2022
Document type:
Article
Affiliation country:
Suecia